DrugPatentWatch

DrugPatentWatch Archives

You are currently viewing the 2006 archives
Click here to return to the current data set

Competitive intelligence on small-molecule drugs and the 80,000 patents covering them

Simple flat-rate subscription plans

Ultimate Plan

$495/ month or  $2,495/ year

Generic Name: aripiprazole

Summary for Generic Name: aripiprazole

Tradenames:1
Patents:3
Applicants:1
NDAs:4
Drug Master File Entries: see list34
Suppliers: see list13
Therapeutic Class:Antipsychotics
Bipolar Agents
Formulation / Manufacturing:see details

Pharmacology for Ingredient: aripiprazole

Tentative approvals for ARIPIPRAZOLE

Applicant Application No. Form Dosage
<disabled><disabled>TABLET; ORAL10MG
<disabled><disabled>TABLET; ORAL15MG
<disabled><disabled>TABLET; ORAL20MG

Clinical Trials for: aripiprazole

Intramuscular Depot Formulation of Aripiprazole as Maintenance Treatment in Patients With Schizophrenia
Status: Completed Condition: Schizophrenia

A Multiple Dose Safety, Tolerability and Pharmacokinetics Study in Adult Patients With Schizophrenia Following Administration of Aripiprazole IM Depot
Status: Completed Condition: Schizophrenia

Aripiprazole and Topiramate on Free-Choice Alcohol Use
Status: Recruiting Condition: Alcohol Dependence

Open Label Drug Interaction Study Evaluating Desvenlafaxine Succinate Sustained Release (DVS SR) 100mg On The Pharmacokinetics Of Aripiprazole When Coadministered To Healthy Subjects
Status: Completed Condition: Pharmacokinetics; Cytochrome P-450 CYP2D6; CYP3A4 Protein, Human

Aripiprazole Treatment for Methamphetamine Dependence Among High-risk Individuals
Status: Completed Condition: Substance Abuse; HIV Infections

Aripiprazole (Abilify®) as an Adjunctive Treatment for Inadequate Response in Major Depressive Disorder
Status: Recruiting Condition: Major Depressive Disorder

Courtesy of ClinicalTrials.org
See more clinical trials for this drug

Litigation for: ARIPIPRAZOLE


Glossary
Applicant Tradename Generic Name Dosage NDA Approval Date Type RLD Patent No. Patent Expiration Patented / Exclusive Use
Otsuka
ABILIFY
aripiprazole
INJECTABLE; INTRAMUSCULAR021866Sep 20, 2006RXYes<disabled>NEW CHEMICAL ENTITY
Otsuka
ABILIFY
aripiprazole
INJECTABLE; INTRAMUSCULAR021866Sep 20, 2006RXYes<disabled>NEW DOSAGE FORM
Otsuka
ABILIFY
aripiprazole
INJECTABLE; INTRAMUSCULAR021866Sep 20, 2006RXYes5,006,528<disabled>ADMINISTRATION OF ARIPIPRAZOLE BY INJECTION
Otsuka
ABILIFY
aripiprazole
INJECTABLE; INTRAMUSCULAR021866Sep 20, 2006RXYes7,115,587<disabled>TREATMENT OF SCHIZOPHRENIA
This preview shows a limited data set
Complete access is available with a Subscription
first patents previous patents next patents last patents

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.

Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided information. There is no warranty that the information contained herein is error free. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Connect with Social Media:

Follow DrugPatentWatch on Twitter Connect with DrugPatentWatch on Linkedin Drug Patents on LinkedIn

Copyright © 2002-2014 thinkBiotech LLC. ISSN: 2162-2639

Other thinkBiotech sites: BiotechUBiotechBlogJournal of Commercial Biotechnology

`abc